CDC publishes guidelines for collaborative practice agreements
WASHINGTON — The Centers for Disease Control and Prevention has published a set of recommendations on collaborative practice agreements between pharmacists and physicians in an effort to improve healthcare quality, under a partnership with the American Pharmacists Association’s philanthropic wing.
The new recommendations, from the CDC’s Division of Heart Disease and Stroke Prevention, are directed at pharmacists, other healthcare providers, payers and decision-makers involved in collaborative practice agreements. A collaborative practice agreement is a formal agreement that allows a physician to refer a patient to a pharmacist for such specific patient care services as travel vaccinations.
"Research shows us that a patient’s control of their blood pressure improves when their care is provided by a team of health professionals," said David Callahan, an official with the division. "This tool kit will play an invaluable role in allowing physicians and pharmacists to work together to give patients optimal care and save lives by controlling blood pressure."
The APhA Foundation provided advice for content based on its consortium on collaborative practice agreements and pharmacists’ patient care services, which took place in January 2012. It also includes examples from three pharmacies that have found success in establishing stronger relationships between pharmacists and other providers.
"It was a pleasure to partner with the CDC to explore the meaningful implementation of collaborative practice agreements," APhA Foundation executive director Mindy Smith said. "The DHDSP at the CDC and the APhA Foundation have a common goal of improving people’s health, and CPAs can help achieve that goal by solidifying collaborative, patient-focused healthcare teams in a variety of practice settings."
Former Genentech COO appointed to Rite Aid board of directors
CAMP HILL, Pa. — Rite Aid has appointed healthcare executive Myrtle Potter to its board of directors, the retail pharmacy chain said Tuesday.
Potter is currently CEO of Myrtle Potter & Co., a Silicon Valley-based consulting firm focused on life sciences and health care, as well as the head of consumer healthcare content company Myrtle Potter Media. She previous served as president of commercial operations and COO at Genentech and has worked at companies like Bristol-Myers Squibb and Merck.
"We are pleased that Myrtle has accepted a position on our board," Rite Aid chairman and CEO John Standley said. "Her extensive knowledge and leadership in health care, particularly in the pharmaceutical industry, will add an important dimension and perspective to our board as we assess how to most effectively grow our business and meet the health and wellness needs of our consumers in a rapidly changing and evolving healthcare environment."
GSK’s Christophe Weber elected as COO of Takeda
OSAKA, Japan — Takeda Pharmaceutical Co., the largest drug maker in Japan, has hired the head of GlaxoSmithKline’s vaccines division as its COO, Takeda said.
Christophe Weber was elected at the drug maker’s board of directors meeting to become COO and candidate as the next CEO. Current president and CEO Yasuchika Hasegawa is expected to be named chairman and CEO.
Weber is currently president and general manager of GSK Vaccines, CEO of GSK Biologicals in Belgium and a member of GSK’s global corporate executive team.
"We have extremely high expectations for Mr. Weber’s contributions to further enhance and accelerate the implementation of Takeda’s global strategy based on his extraordinary and broad business experiences, including an impressive track record in top global pharmaceutical companies," Hasegawa said.